Gallagher hails from the School of Pharmacy at Temple University in Pennsylvania where he serves as the director of the residency program and clinical professor and clinical pharmacy specialist in infectious disease.
Throughout his esteemed career, Gallagher has been responsible for publications, abstracts and book chapters.
He has been the president of the Society of Infectious Diseases Pharmacists and has had leadership positions in other societies.
Gallagher is an author of Antibiotics Simplified, which is it its fourth edition, and currently serves on the Infectious Diseases Specialty Council of the board of Pharmacy Specialties.
His research interests focus on pharmacotherapy of resistant infections, antimicrobial clinical pharmacodynamics, and antibiotic stewardship.
As editor in chief, Gallagher will work closely with Contagion's editorial team to deliver information about recent medical developments and research in infectious diseases.
Additionally, Dr. Gallagher will offer exclusive insights about emerging trends in the infectious disease community.
Contagion is a news resource covering all areas of infectious disease.
Through its website, quarterly journal, email newsletters, social media outlets and Outbreak Monitor, it provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment and prevention of infectious diseases.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy